title: Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs†.
abstract: Sixty-four dogs were treated with single-agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression-free survival (PFS) for treated dogs was 66 days. The median survival time (MST) for this group was 116 days and was significantly improved compared to a MST of 12 days for untreated control dogs (P = 0.0001). Biologic response was significantly associated with improved PFS (P < 0.0001) and OS (P < 0.0001). Univariate analysis identified larger tumour size as a variable negatively associated with PFS. The high rate of clinical benefit and improved MST suggest that DOX has activity in canine cHSA.
authors.affiliation: The Oncology Service, Washington, DC, USA.|Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Mullin
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.|North Carolina State University, Raleigh, NC, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Arkans
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.
authors.forename: C D
authors.initials: CD
authors.lastname: Sammarco
authors.affiliation: University of Wisconsin School of Veterinary Medicine, Madison, WI, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.|BluePearl Veterinary Partners, New York, NY, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Britton
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.|Hope Veterinary Specialists, Malvern, PA, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Vickery
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.|Veterinary Specialty & Emergency Center, Levittown, PA, USA.
authors.forename: R E
authors.initials: RE
authors.lastname: Risbon
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.|BluePearl Veterinary Partners, New York, NY, USA.
authors.forename: J
authors.initials: J
authors.lastname: Lachowicz
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.|Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Burgess
authors.affiliation: The Oncology Service, Washington, DC, USA.|Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Manley
authors.affiliation: Red Bank Veterinary Hospital, Tinton Falls, NJ, USA.|Hope Veterinary Specialists, Malvern, PA, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Clifford
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D016022:Case-Control Studies; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006338:Heart Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin
keywords: chemotherapy; metastasis; oncology; small animal; surgical oncology; tumour biology